What does GSK’s $58 cash offer mean for RAPT shareholders?

It sets a clear takeout price. Shares typically trade near $58, often at a small discount until closing to reflect time value and deal risk. If the deal closes, tendered shares receive $58 in cash. If it breaks, the stock could fall toward pre-deal levels, so investors must weigh spread versus risk.

When will the RAPT acquisition likely close?

GSK expects to launch a tender offer within 10 business days of signing. The companies target a Q1 2026 closing, subject to customary conditions and approvals. Track the tender launch, minimum tender conditions, and regulatory filings. Any milestones, delays, or updates can change the merger spread and the expected timeline.

Why did RAPT stock today surge about 63% premarket?

The all-cash $58 per-share offer valued RAPT at about $2.2 billion and provided price certainty. That premium and reduced financing risk attracted merger-arbitrage buyers, pushing shares rapidly toward the offer price. The market also sees strategic value in ozureprubart, a phase IIb anti-IgE food allergy drug that fits GSK’s immunology focus.

Global Market Insights

RAPT Stock Today: January 20 Surges 63% on GSK’s $58 Cash Offer

ByHuzaifa Zahoor January 20, 2026January 20, 2026

RAPT stock today is soaring after GSK agreed to buy RAPT for $58 per share in cash, valuing the company at $2.2 billion. Shares spiked about 63% in premarket trade as the offer set a near-term anchor for the price. The deal adds ozureprubart, a phase IIb anti-IgE food allergy drug, to GSK’s immunology pipeline. A tender offer is expected within 10 business days of signing, with closing targeted for Q1 2026, subject to customary conditions and approvals.